Travere Therapeutics Inc. (TVTX)$44.43
Market Cap: 1.90 BCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Travere Therapeutics Inc. (TVTX).
HEALTHCARE
BIOTECHNOLOGY
DCF ready
Valuation
47.9x
EV/FCF, 2.1% FCF yield
Quality
-22.2%
ROIC, 7.7% FCF margin
Growth
19.9%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 2.7x current ratio
Superinvestors
0
No tracked positions
Strengths to research
- Revenue compounded at 19.9% over five years.
- Debt/equity looks manageable at 0.0x.
- 10 annual periods are available for trend analysis.
Watchouts
- P/FCF is elevated at 50.3x.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for TVTX.
Grade F
19
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| TVTX Target | Travere Therapeutics Inc. | $1.9B | -153.2x | 47.9x | -22.2% | 19.9% | 7.7% | N/A | N/A | N/A |
| EWTX | Edgewise Therapeutics Inc. | $1.7B | -20.1x | -11.6x | -0.0% | N/A | N/A | N/A | N/A | N/A |
| NAMS | Newamsterdam Pharma Co Nv | $2.2B | -20.6x | -11.7x | -29.7% | N/A | -657.8% | N/A | N/A | N/A |
| ADPT | Adaptive Biotechnologies Corp. | $1.5B | -35.6x | -29.7x | -27.2% | 23.0% | -17.7% | N/A | N/A | N/A |
| MESO | Mesoblast Ltd Spon ADR | $1.4B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| IMVT | Immunovant Inc. | $2.6B | -12.3x | -4.1x | -59.3% | N/A | N/A | N/A | N/A | N/A |
| PHVS | Pharvaris NV | $1.0B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| RCKT | Rocket Pharmaceuticals Inc. | $838.3M | -1.5x | -4.0x | -80.5% | N/A | N/A | N/A | N/A | N/A |
| PCVX | Vaxcyte Inc. | $4.4B | -8.4x | -6.3x | -0.0% | N/A | N/A | N/A | N/A | N/A |
Financial Charts
No financial data available for TVTX (annual).